MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lefkowitz, R. J.
Right arrow Articles by Luttrell, L. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lefkowitz, R. J.
Right arrow Articles by Luttrell, L. M.

Vol. 62, Issue 5, 971-974, November 2002

PERSPECTIVE

Dancing with Different Partners: Protein Kinase A Phosphorylation of Seven Membrane-Spanning Receptors Regulates Their G Protein-Coupling Specificity

Robert J. Lefkowitz, Kristen L. Pierce, and Louis M. Luttrell

Departments of Medicine and Biochemistry and Howard Hughes Medical Institute, Duke University Medical Center, Durham, North Carolina (R.J.L., K.L.P.); The Geriatrics Research, Education and Clinical Center, Durham Veterans Affairs Medical Center, Durham, North Carolina (L.M.L.)

    Article
Top
Article
References

In simpler times, studies of G protein-coupled receptor (GPCR) signaling focused almost exclusively on pathways characterized by a small number of sequential events, largely confined to the plasma membrane [for example, activation of adenylyl cyclase by the beta 2AR (Lefkowitz, 2000)]. However, in recent years, there has been a growing awareness that GPCRs stimulate much more complex pathways that ultimately connect events at the plasma membrane to nuclear events, such as gene transcription. Receptor regulation of mitogen-activated protein kinases is a case in point. The complexity, heterogeneity, and apparent redundancy of the pathways that lead from the seven membrane-spanning and tyrosine kinase receptors in the plasma membrane to ERK in the cytosol are dazzling and involve almost every known type of signaling molecule (Luttrell et al., 1999; Gutkind, 2000). Moreover, this remarkable multiplicity of pathways extends to individual receptors. Thus, a single receptor may signal to ERK by numerous pathways, the importance of which may vary dramatically between different cell types or cell lines or even among different isolates of the "same" cell line. Therefore, the very general conclusions drawn by Friedman et al. (2002) concerning the "dominant mechanism for beta 2AR activation of ERK" in an article in this issue of Molecular Pharmacology represent a broad and potentially misleading simplification. However, this article provides an excellent focal point for discussion of the complexity of signaling pathways that lead from GPCRs to downstream effectors such as ERK and an occasion to highlight an interesting mechanism for regulating the signaling specificity of such receptors: the "switching" of their G protein-coupling specificity by PKA-mediated receptor phosphorylation.

The most thoroughly studied actions of the Gs coupled beta 2AR are mediated by cAMP and PKA. The first Gs-dependent effect of beta 2ARs on ERK discovered was cAMP-mediated inhibition of ERK (Cook and McCormick, 1993; Wu et al., 1993; Crespo et al., 1995). This is due to the Galpha s-dependent activation of PKA, leading to phosphorylation and inhibition of c-Raf1 (Cook and McCormick, 1993; Wu et al., 1993). However, stimulation of the beta 2AR can also activate ERK via a Gs dependent pathway in some cell types. This has been demonstrated in human embryonic kidney (HEK) 293 cells (Schmitt and Stork, 2000) and S49 lymphoma cells (Wan and Huang, 1998). This pathway is pertussis toxin-insensitive and seems to involve Src, the small G protein Rap1, and the B-Raf isoform, rather than c-Raf1. It is independent of Ras. This pathway, originally described by Schmitt and Stork in 293 cells (Schmitt and Stork, 2000), is now recharacterized by Friedman et al. (2002).

However, a growing body of in vivo and in vitro data indicate that some actions of the beta 2AR are transduced via Gi. These include activation of the enzymes ERK (Daaka et al., 1997), AKT (Zhu et al., 2001), phosphoinositide-3 kinase (Zhu et al., 2001) and certain receptor tyrosine kinases (Maudsley et al., 2000), and inhibition of adenylyl cyclase (Lawler et al., 2001). Gi-mediated activation of ERK by the beta 2AR has been demonstrated in cultured HEK293 cells (Daaka et al., 1997), monkey kidney cells (COS-7) (Maudsley et al., 2000), Chinese hamster ovary (CHO) cells (Zamah et al., 2002), and cultured rat cardiac myocytes (Zou et al., 1999). This Gi-mediated pathway is pertussis toxin-sensitive and seems to be transduced by Gbeta gamma subunits, Src, Ras, and c-Raf1, and may involve transactivation of the epidermal growth factor receptor (Daaka et al., 1997; Luttrell et al., 1999; Zou et al., 1999; Gutkind, 2000; Maudsley et al., 2000; Lawler et al., 2001; Zhu et al., 2001; Zamah et al., 2002).

These two pathways are schematically depicted in Fig. 1. A particularly interesting aspect of the Gi-mediated stimulation of ERK via the beta 2AR is that it seems to require prior phosphorylation of the receptor by PKA (Daaka et al., 1997), a mechanism previously demonstrated to "desensitize" beta 2ARs by decreasing their coupling to Gs (Benovic et al., 1985; Pitcher et al., 1992). PKA phosphorylation simultaneously diminishes beta 2AR coupling to Gs and increases coupling to Gi. This mechanism has been referred to as G protein "switching" (Daaka et al., 1997). That some regulatory mechanism would be required to "switch" or alter the inherent coupling of the beta 2AR and thus enable its interaction with Gi was clear, in retrospect, from reconstitution experiments performed almost 20 years ago (Cerione et al., 1985). These demonstrated, in reconstituted systems consisting only of purified receptors and G proteins, that the beta 2AR, although coupling robustly to Gs, was virtually devoid of coupling to Gi.


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 1.   Gs- and Gi-mediated pathways for ERK activation by the beta 2AR. Signaling intermediates colored green are shared by both pathways, whereas those in salmon are unique to one pathway.

The first indication that PKA-mediated phosphorylation of the beta 2AR might do more than simply "desensitize" the receptor by inhibiting its coupling to Gs was provided by Okamoto et al. (1991). They demonstrated that a short peptide derived from the third cytoplasmic loop of the beta 2AR effectively activated purified Gs but only very weakly activated Gi in vitro. This peptide contains one of the two consensus PKA phosphorylation sites found in the receptor. When the peptide was phosphorylated by PKA, its ability to activate Gs was dramatically reduced, whereas its ability to activate Gi was reciprocally increased.

These results are essentially identical to findings in recent in vitro reconstitution studies with the intact recombinant human beta 2AR and recombinant Gs and Gi (Zamah et al., 2002). Reconstituted native beta 2AR mediates robust activation of Gs but not Gi. When the receptor is phosphorylated in vitro by PKA, Gs coupling is reduced, but Gi activation is markedly enhanced. The results are replicated when a purified recombinant beta 2AR, in which the PKA phosphorylation sites are mutated (Sright-arrowD) to mimic the effects of phosphorylation, is tested in the reconstituted system. Again, Gs coupling is impaired, whereas Gi stimulation is increased (Zamah et al., 2002).

That PKA-mediated phosphorylation of the beta 2AR might regulate its coupling to Gs and Gi in cells was first appreciated in studies performed using a line of HEK293 cells; Daaka et al. (1997) demonstrated that activation of ERK by endogenous beta 2ARs was mediated largely by Gi (pertussis toxin-sensitive). However, concomitant PKA activation seemed to be required because the ERK activation was blocked by the PKA inhibitor H89, as was the ability of the receptor to stimulate [32P]GTP azidoanilido loading of Gi in cell membranes. Gi-mediated inhibition of forskolin-stimulated adenylyl cyclase by the beta 2AR in HEK293 cells was also blocked by pertussis toxin or H89 but not by a PKC inhibitor (Lawler et al., 2001). That the receptor was the site of the required PKA phosphorylation was suggested by the failure of a mutant beta 2AR (Sright-arrowA), which was not a substrate for PKA, to activate ERK when transfected into these cells (Daaka et al., 1997).

Gi-mediated activation of ERK by the beta 2AR, which requires prior activation of PKA, has subsequently been demonstrated in murine submandibular gland cells (Luo et al., 1999), rat cardiac myocytes (Zou et al., 1999), and CHO cells (Zamah et al., 2002). Moreover in the latter two systems, as in the original studies with HEK293 cells, the beta 2AR itself was implicated as the locus of PKA phosphorylation, because phosphorylation site mutants of the beta 2AR (PKA-) failed to activate ERK or acted as dominant negatives for isoproterenol-stimulated ERK activation. Recently, evidence has been presented suggesting that this switching mechanism operates in vivo in the mouse heart (Hasseldine et al., 2002).

An entirely analogous switching mechanism has been reported for the Gs-coupled mouse prostacyclin receptor (Lawler et al., 2001). In HEK293 cells, this receptor can activate Gs (stimulate cAMP accumulation), Gi (inhibit forskolin stimulated cAMP accumulation), and Gq (activate phospholipase C leading to calcium release). However, the Gi- and Gq-mediated responses are blocked by H89, and a receptor point mutant (S357A) that cannot undergo PKA phosphorylation activates only Gs. Moreover, whereas the wild-type receptor can be immunoprecipitated with Gs, Gi, and Gq in an agonist-dependent manner, the mutant receptor interacts only with Gs. Not only do these studies confirm the Gs-to-Gi switching mechanism, they extend it to another G protein, Gq (Lawler et al., 2001). A further interesting twist is that the human prostacyclin receptor, which has a PKC site in place of the PKA site of the mouse receptor, couples to Gs and Gq but not Gi. Substitution of the PKC site by a PKA site by mutagenesis enables PKA-dependent coupling to Gi, which is lost on further mutagenesis to remove the relevant serine from this position (Miggin and Kinsella, 2002). Thus, at present, it seems that PKA, but not PKC, can mediate such switching phenomena.

The studies reviewed above (summarized in Table 1), provide compelling support for the idea that PKA-mediated phosphorylation of GPCRs regulates their coupling to different G proteins, especially Gi. So why then do Friedman et al. (2002) fail to observe this switching mechanism in their 293 cells, a line previously used by others to demonstrate just such effects for both the beta 2AR (Daaka et al., 1997; Lawler et al., 2001) and the prostacyclin receptor (Lawler et al., 2001; Miggin and Kinsella, 2002)? The most obvious lesson is that transformed cell lines are not uniform in their properties. During prolonged culture, such lines alter chromosome number, gene expression signaling pathways used, and even morphology. Thus, it is not possible to draw from any single study of GPCR-mediated ERK activation in a cultured cell line any valid, generally applicable conclusions about the "dominant pathway of ERK activation" by that receptor.


                              
View this table:
[in this window]
[in a new window]
 
TABLE 1
PKA-mediated receptor phosphorylation switches G protein-coupling specificity

Lines referred to as HEK293 have a remarkable heterogeneity; for example, we recently tested the sensitivity to pertussis toxin of ERK activity stimulated by isoproterenol through endogenous beta 2ARs in nine different isolates of HEK293 cells and found that this varied from 0 to 100% (Fig. 2). Friedman et al. (2002) reported a minimal effect of pertussis toxin on ERK activation by the beta 2AR, whereas, by contrast, Daaka et al. (1997) reported that the beta 2AR-mediated effect on ERK was quite sensitive to pertussis toxin. Based on these findings, the divergent effects of a PKA-beta 2AR mutant receptor on ERK activity in the different studies are quite predictable. In the HEK 293 cells used by Friedman et al. (2002), the beta 2AR activates ERK almost exclusively via Gs. Because such signaling is inhibited by PKA phosphorylation of the receptor (Fig. 1), the PKA-beta 2AR should be normally active or superactive in these cells. Conversely, in the cells used by Daaka et al. (1997), the beta 2AR activates ERK primarily via Gi. Because such signaling is enabled by receptor phosphorylation (Fig. 1), the PKA-beta 2AR should be inactive in these cells. This is precisely what was found in the two studies (Daaka et al., 1997; Friedman et al., 2002).


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 2.   Pertussis toxin sensitivity of beta 2AR stimulated ERK activity in different isolates of HEK 293 cells. 293 cells plated in 12-well dishes (150,000 cells/well) were serum-starved and pertussis toxin-treated (PTX, 100 ng/ml) overnight before stimulation with 1 µM isoproterenol (ISO) for 5 min at 37°C. Cell lysates were prepared, and immunoblotting performed following standard procedures using a phospho-ERK specific antibody (Cellular Signaling, Beverly, MA). A representative experiment is shown, but experiments were repeated at least three times with each isolate. The three isolates shown are representative of nine that were studied. In two of the nine isolates, isoproterenol did not stimulate ERK phosphorylation. Isolates were obtained from various investigators at Duke University Medical Center and from the American Type Culture Collection (Manassas, VA).

Currently unclear, however, are the specific differences that account for the marked variability in pathway usage between these different isolates of 293 cells. This largely unstudied problem may hold clues to understanding important aspects of cellular regulation. Recently developed gene chip array and proteomics approaches have obvious applicability here, as do more specific, hypothesis-driven approaches focusing on expression levels of the obvious known intermediates in the various pathways. Moreover, to understand the ultimate physiological outcome, the relative contributions of each of the different pathways need to be characterized both in primary cells and in vivo.

In conclusion, the article by Friedman et al. (2002) illustrates the confusions of interpretation that result from failing to appreciate the diversity and complexity of mechanisms that can be used by a single receptor to signal to a very downstream effector in different cells. In a final ironic twist, the pathway globally assigned by Friedman et al. as "the dominant pathway for beta 2AR activation of ERK" (Gs right-arrow AC right-arrow PKA right-arrow Src right-arrowright-arrow Rap1 right-arrowright-arrowright-arrow ERK) has recently been shown to inhibit Ras-dependent ERK activity in NIH3T3 fibroblasts (Schmitt and Stork, 2002), thereby inhibiting cell growth.

    Acknowledgments

We thank Musa Zamah, Seungkirl Ahn, and Darrell Capel for help with experiments.

    Footnotes

Received August 1, 2002; Accepted August 6, 2002

This work was supported in part by National Institutes of Health grant HL16037. R.J.L. is an Investigator of the Howard Hughes Medical Institute.

Address correspondence to: Dr. Robert J. Lefkowitz, Howard Hughes Medical Institute, Duke University Medical Center, Durham, NC 27710. E-mail: lefko001{at}receptor-biol.duke.edu

    Abbreviations

GPCR, G protein-coupled receptor; AR, adrenergic receptor; ERK, extracellular signal-regulated kinase; HEK, human embryonic kidney; PKC, protein kinase C.

    References
Top
Article
References


0026-895X/02/6205-971-974$3.00
Mol Pharmacol, 62:971-974, 2002
Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
A. Hu, G. Nino, J. S. Grunstein, S. Fatma, and M. M. Grunstein
Prolonged heterologous {beta}2-adrenoceptor desensitization promotes proasthmatic airway smooth muscle function via PKA/ERK1/2-mediated phosphodiesterase-4 induction
Am J Physiol Lung Cell Mol Physiol, June 1, 2008; 294(6): L1055 - L1067.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
E. L. Maillet, N. Pellegrini, C. Valant, B. Bucher, M. Hibert, J.-J. Bourguignon, and J.-L. Galzi
A novel, conformation-specific allosteric inhibitor of the tachykinin NK2 receptor (NK2R) with functionally selective properties
FASEB J, July 1, 2007; 21(9): 2124 - 2134.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
W. A. Goddard III and R. Abrol
3-Dimensional Structures of G Protein-Coupled Receptors and Binding Sites of Agonists and Antagonists
J. Nutr., June 1, 2007; 137(6): 1528S - 1538S.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
M. D. Houslay, G. S. Baillie, and D. H. Maurice
cAMP-Specific Phosphodiesterase-4 Enzymes in the Cardiovascular System: A Molecular Toolbox for Generating Compartmentalized cAMP Signaling
Circ. Res., April 13, 2007; 100(7): 950 - 966.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
L. Ma and G. Pei
beta-arrestin signaling and regulation of transcription
J. Cell Sci., January 15, 2007; 120(2): 213 - 218.
[Abstract] [Full Text] [PDF]


Home page
J. Gerontol. A Biol. Sci. Med. Sci.Home page
W. E. Schutzer, H. Xue, J. F. Reed, and S. L. Mader
Effect of Age on Vascular {beta}2-Adrenergic Receptor Desensitization Is Not Mediated by the Receptor Coupling to G{alpha}i Proteins.
J. Gerontol. A Biol. Sci. Med. Sci., September 1, 2006; 61(9): 899 - 906.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
N. J. Smith and L. M. Luttrell
Signal Switching, Crosstalk, and Arrestin Scaffolds: Novel G Protein-Coupled Receptor Signaling in Cardiovascular Disease
Hypertension, August 1, 2006; 48(2): 173 - 179.
[Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. K. Shenoy, M. T. Drake, C. D. Nelson, D. A. Houtz, K. Xiao, S. Madabushi, E. Reiter, R. T. Premont, O. Lichtarge, and R. J. Lefkowitz
beta-Arrestin-dependent, G Protein-independent ERK1/2 Activation by the beta2 Adrenergic Receptor
J. Biol. Chem., January 13, 2006; 281(2): 1261 - 1273.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. J. Lynch, G. S. Baillie, A. Mohamed, X. Li, C. Maisonneuve, E. Klussmann, G. van Heeke, and M. D. Houslay
RNA Silencing Identifies PDE4D5 as the Functionally Relevant cAMP Phosphodiesterase Interacting with {beta}Arrestin to Control the Protein Kinase A/AKAP79-mediated Switching of the {beta}2-Adrenergic Receptor to Activation of ERK in HEK293B2 Cells
J. Biol. Chem., September 30, 2005; 280(39): 33178 - 33189.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
T. Seck, M. Pellegrini, A. M. Florea, V. Grignoux, R. Baron, D. F. Mierke, and W. C. Horne
The {Delta}e13 Isoform of the Calcitonin Receptor Forms a Six-Transmembrane Domain Receptor with Dominant-Negative Effects on Receptor Surface Expression and Signaling
Mol. Endocrinol., August 1, 2005; 19(8): 2132 - 2144.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
R. Nasrallah and R. L. Hebert
Prostacyclin signaling in the kidney: implications for health and disease
Am J Physiol Renal Physiol, August 1, 2005; 289(2): F235 - F246.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
G. Barthet, F. Gaven, B. Framery, K. Shinjo, T. Nakamura, S. Claeysen, J. Bockaert, and A. Dumuis
Uncoupling and Endocytosis of 5-Hydroxytryptamine 4 Receptors: DISTINCT MOLECULAR EVENTS WITH DIFFERENT GRK2 REQUIREMENTS
J. Biol. Chem., July 29, 2005; 280(30): 27924 - 27934.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
C.-K. Yeh, P. M. Ghosh, H. Dang, Q. Liu, A. L. Lin, B.-X. Zhang, and M. S. Katz
{beta}-Adrenergic-responsive activation of extracellular signal-regulated protein kinases in salivary cells: role of epidermal growth factor receptor and cAMP
Am J Physiol Cell Physiol, June 1, 2005; 288(6): C1357 - C1366.
[Abstract] [Full Text] [PDF]


Home page
Protein Eng Des SelHome page
V.-P. Jaakola, J. Prilusky, J. L. Sussman, and A. Goldman
G protein-coupled receptors show unusual patterns of intrinsic unfolding
Protein Eng. Des. Sel., February 1, 2005; 18(2): 103 - 110.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
D. Fan, P. M. Bryan, L. K. Antos, R. J. Potthast, and L. R. Potter
Down-Regulation Does Not Mediate Natriuretic Peptide-Dependent Desensitization of Natriuretic Peptide Receptor (NPR)-A or NPR-B: Guanylyl Cyclase-Linked Natriuretic Peptide Receptors Do Not Internalize
Mol. Pharmacol., January 1, 2005; 67(1): 174 - 183.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Keiper, M. B. Stope, D. Szatkowski, A. Bohm, K. Tysack, F. vom Dorp, O. Saur, P. A. Oude Weernink, S. Evellin, K. H. Jakobs, et al.
Epac- and Ca2+-controlled Activation of Ras and Extracellular Signal-regulated Kinases by Gs-coupled Receptors
J. Biol. Chem., November 5, 2004; 279(45): 46497 - 46508.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Beom, D. Cheong, G. Torres, M. G. Caron, and K.-M. Kim
Comparative Studies of Molecular Mechanisms of Dopamine D2 and D3 Receptors for the Activation of Extracellular Signal-regulated Kinase
J. Biol. Chem., July 2, 2004; 279(27): 28304 - 28314.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Breit, M. Lagace, and M. Bouvier
Hetero-oligomerization between {beta}2- and {beta}3-Adrenergic Receptors Generates a {beta}-Adrenergic Signaling Unit with Distinct Functional Properties
J. Biol. Chem., July 2, 2004; 279(27): 28756 - 28765.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
L. Iacovelli, L. Capobianco, M. Iula, V. Di Giorgi Gerevini, A. Picascia, J. Blahos, D. Melchiorri, F. Nicoletti, and A. De Blasi
Regulation of mGlu4 Metabotropic Glutamate Receptor Signaling by Type-2 G-Protein Coupled Receptor Kinase (GRK2)
Mol. Pharmacol., May 1, 2004; 65(5): 1103 - 1110.
[Abstract] [Full Text]


Home page
Pharmacol. Rev.Home page
S. L. Kirstein and P. A. Insel
Autonomic Nervous System Pharmacogenomics: A Progress Report
Pharmacol. Rev., March 1, 2004; 56(1): 31 - 52.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
G. B. Bolger, A. McCahill, E. Huston, Y.-F. Cheung, T. McSorley, G. S. Baillie, and M. D. Houslay
The Unique Amino-terminal Region of the PDE4D5 cAMP Phosphodiesterase Isoform Confers Preferential Interaction with {beta}-Arrestins
J. Biol. Chem., December 5, 2003; 278(49): 49230 - 49238.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
J. G. Baker, I. P. Hall, and S. J. Hill
Agonist and Inverse Agonist Actions of {beta}-Blockers at the Human {beta}2-Adrenoceptor Provide Evidence for Agonist-Directed Signaling
Mol. Pharmacol., December 1, 2003; 64(6): 1357 - 1369.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
R. A. Ally, K. L. Ives, E. Traube, I. Eltounsi, P.-W. Chen, P. J. Cahill, J. F. Battey, M. R. Hellmich, and G. S. Kroog
Agonist- and Protein Kinase C-Induced Phosphorylation Have Similar Functional Consequences for Gastrin-Releasing Peptide Receptor Signaling via Gq
Mol. Pharmacol., October 1, 2003; 64(4): 890 - 904.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
G. S. Baillie, A. Sood, I. McPhee, I. Gall, S. J. Perry, R. J. Lefkowitz, and M. D. Houslay
beta -Arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates beta -adrenoceptor switching from Gs to Gi
PNAS, February 4, 2003; 100(3): 940 - 945.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lefkowitz, R. J.
Right arrow Articles by Luttrell, L. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lefkowitz, R. J.
Right arrow Articles by Luttrell, L. M.


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics